Elemental Impurities Regulations View from a CRO

Overview


RSSL-WP-Pharma-2016-Elemental-Impurities-Regulations-View-from-a-CRO.png

Regulatory control of elemental impurities in pharmaceutical products has long been discussed, with both the European Pharmacopeia (EP) and the United States Pharmacopeia (USP) having planned on issuing specific chapters relating to contamination from elemental substances. New regulations have been postponed several times, most recently to take into consideration the guidance from The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). With this document now in place the relevant pharmacopeias are almost certainly finalised as to their respective approaches to the implementation of these regulations.

In this white paper, an overview will be given on how the regulations have evolved through the pharmacopeias, how the ICH has impacted these regulations, how these could be implemented by manufacturers and the role of CROs in this process.

This content is provided by RSSL, and any views and opinions expressed do not necessarily reflect those of Outsourcing-Pharma.com

Download Now


Latest Content

Extractables and leachables analysis of pharmaceutical products

Extractables and leachables analysis of pharmaceutical products

Paid for and content provided by RSSL

A crucial undertaking when releasing pharmaceutical products for the market, is to determine the purity of the final product, necessitating the need to determine its impurity profile. Traditionally, this was concerned only with those impurities arising...

Related Resources

Supplier Info Centre

RSSL-SIC-Pharma-2016.png

For more product information visit RSSL.